Important note: Information in this article was accurate in September 2006. The state of the art may have changed since the publication date.
Atazanavir/r monotherapy and CNS penetration
HIV Treat Bull - Vol. 7, No. 7/8, September 2006
Vernazza and colleagues presented results looking at the compartmental effect of reducing treatment to ritonavir-boosted atazanavir monotherapy in 30 patients (28 male) suppressed to <50 copies/mL on triple therapy.
HIV viral load was measured every 4 weeks, and semen and cerebro-spinal fluid (CSF) samples were obtained from consenting patients at baseline (semen) and Wk24 (semen+CSF). The primary endpoint was defined as 2 consecutive viral load values >400 copies/mL.
One patient failed monotherapy at week 8 who was retrospectively shown to have previously failed a PI based HAART. One patient prematurely terminated treatment at week 20. All remaining 27 patients had suppressed viral load <100 copies/mL at week 24. 22 patients still remain on ATV/r with a median follow-up of 19 months (6 –29) and a mean CD4 increase of 78 cells/mL.
19 CSF samples were obtained at week 24, 3 patients had detectable HIV-RNA in CNS (2.2, 2.9, 3.8 log10 cp/ml) despite fully suppressed HIV-RNA in blood, although all three CSF samples were wild type. Viral load was undetectable in all semen samples (n=15).
The authors concluded “limited penetration of PI into CNS may result in replication of wild-type HIV in the CNS in a relevant subset of patients. As the consequence of low-level HIV replication in different compartments is not known, future monotherapy trials should include careful monitoring of compartments other than blood. Mono-maintenance, however, might be a valid option for future studies.”
Ref:
Vernazza P, Daneel S, Schiffer V et al. Risk of CNS-compartment failure on PI monotherapy (ATARITMO-study). Poster abstract WEPE0073.
2006-09-10
IB060709-13
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.